Navigation Links
Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
Date:9/19/2013

analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-17/PFE]

--

GlaxoSmithKline plc Research Report

On September 16, 2013, GlaxoSmithKline plc (GlaxoSmithKline) announced that the US FDA has granted Priority Review designation to the Company's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E and V600 K mutation. GlaxoSmithKline informed that the FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of January 8, 2014 for the Mekinist supplement, and January 9, 2014 for the Tafinlar supplement. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-09-17/GSK]

--

Sanofi SA Research Report

On September 17, 2013, Sanofi SA (Sanofi) and its subsidiary Genzyme announced that the European Commission has granted marketing authorization for Lemtrada. Genzyme informed that it plans to begin launching Lemtrada and the previously approved Aubagio in the EU soon. "The approvals of Lemtrada and Aubagio in the European Union represent an important milestone for Genzyme and demonstrate our focus on scientific innovation and commitment to multiple sclerosis patients. This is particularly exciting as the EU approval is the first for Lemtrada globally," said David Meeker, M.D., President and CEO of Genzyme. "The Lemtrada clinical trial data support its potential to meaningfully address disability in active RRMS patients, while Aubagio's efficacy, safety and convenient dosing may provid
'/>"/>

SOURCE Investors' Reports
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
3. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
4. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
5. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
6. Varian Medical Systems and Siemens Healthcare Announce Global Collaboration to Advance Clinical Capabilities and Offerings in Radiotherapy and Radiosurgery
7. New Clinical Endocrinology Guidelines Support Lp-PLA2 Measurement For Risk Assessment of Coronary Artery Disease
8. First Patient Treated in U.S. Clinical Study of Cohera Medicals TissuGlu® Surgical Adhesive
9. Michael J. Fox Foundation-Funded Study Identifies Best Dyskinesia Clinical Rating Scale
10. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
11. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/32cmct/inferior_vena ) ... Cava (IVC) Filters - Global Trends, Estimates and Forecasts, ... http://photos.prnewswire.com/prnh/20130307/600769 Global Inferior Vena ... million by 2016. The North America ... value while Europe claims approximately ...
(Date:12/15/2014)... Norway , December 15, 2014 ... innovative drugs for aggressive drug resistant cancers, today announces ... in a private placing from new and existing investors. ... financing to support the development of its pipeline of ... program for its lead drug candidate, BGB324, a first-in-class ...
(Date:12/15/2014)... Dec. 15, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... been added to the NASDAQ Biotechnology Index (NBI). ... become effective upon market open on December 22, ... designed to track the performance of a set ... biotechnology or pharmaceutical according to the Industry Classification ...
Breaking Medicine Technology:Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4BerGenBio Completes NOK90 Million Fundraising 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... new understanding of,the role played by the protein ... novel therapies to rebuild muscle tissue,damaged by disease, ... Institute for Cancer Research and Molecular Medicine at ... The researchers reported their findings, "Cdk9-55: A ...
... implantable,medical device, developed in collaboration with Mayo Clinic ... alternative to existing,bariatric surgeries, according to findings published ... In a six-month open label trial involving three ... obese participants who received the,vagal nerve blocking device, ...
Cached Medicine Technology:International Team Locates Key Player in Muscle Regeneration 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 2Device Blocking Stomach Nerve Signals Shows Promise in Obesity 3
(Date:12/17/2014)... Dr. Myo Nwe is the co-author of ... the Future” and co-founder of the Ace Medical Weight Loss ... takes a broad look at the industry of weight loss, ... scrutiny. On film and in television shows, however, she says ... social aspects and played for basic laughs, which she believes ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... one worrisome phenomenon is when an illness that originated in ... as zoonosis -- is not uncommon and keeps researchers on ... disease might make inroads into the human population. A ... the culprits in this case were guinea pigs. More specifically, ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. ... to improve overall health, but a growing body of evidence ... new review finds. In fact, the benefits were similar ... lead researcher Paula Chu, a doctoral candidate at Harvard University,s ... clinical trials, found that people randomly assigned to take yoga ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Main Street ... clinic, is weighing in on a new study providing ... on the oral hygiene of children. , Sufficient enough ... drinks, such as pop or juice drinks, with the ... looming, however, is whether drinks listed as 100% fruit ...
Breaking Medicine News(10 mins):Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2
... offers a significantly higher survival rate than either external-beam radiation ... researchers at UCSF. The differences among therapies were more ... researchers say, that in many cases surgery should play a ... that is likely to recur or spread. ...
... Reinberg HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay ... having a miscarriage stand the best chance of having a ... The time that couples should wait after a miscarriage ... among medical experts. Some doctors say there is no reason ...
... HealthDay Reporter , THURSDAY, Aug. 5 (HealthDay News) ... a lowered risk of heart disease and diabetes, being ... of glaucoma, Harvard researchers say. This new finding ... of developing primary open-angle glaucoma (POAG), one of the ...
... Researchers looking for differences in eating habits of African ... diabetes uncovered an unexpected result: No matter what the blood ... same. African Americans are 1.8 times more likely to ... be obese than are non-Hispanic whites, according to federal health ...
... published today in the scientific journal Addiction ... the manufacture of methamphetamine have caused a drop in ... In 2005 Mexico began controlling its ... manufacture of methamphetamine), and in 2008 it became the ...
... hard to find, here,s good news for the under-qualified: ... ( http://www.fasebj.org ) shows that being a highly ... taking on leading management positions at research institutions. This ... may exist at research institutions where top-cited scientists either ...
Cached Medicine News:Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 2Health News:Surgery better than radiation, hormone treatments for some prostate cancer, study shows 3Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 2Health News:Women Can Safely Get Pregnant Right After Miscarriage, Study Shows 3Health News:Excess Weight May Protect Women From Type of Glaucoma 2Health News:Excess Weight May Protect Women From Type of Glaucoma 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 2Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 3Health News:Diabetes or not, dietary habits of Aftrican-Americans are similar 4Health News:Help wanted: Highly cited researchers needed for high-ranking positions at research institutions 2
... in the field of Urodynamics, Albyn Medical recognised ... new chair is manufactured from the highest quality ... can be improved considerably if the patient is ... this aspect was given a high priority in ...
The Triage Drugs of Abuse Panel is the leading rapid drug screen used by U.S. hospitals. The Triage Drugs of Abuse Panel is a small, handheld urine test that provides qualitative results for up to n...
... The Advanced Model 3900 Multi-Sample ... for laboratories processing moderate to high ... industry-preferred method of freezing-point technology for ... combined with high, continuous throughput, the ...
... The Advanced® 2020 Multi-Sample Osmometer provides ... industrial, and research settings. These results ... freezing-point method, which determines total concentration. ... on-board data management, automated sample handling, ...
Medicine Products: